Betz Michael
Known title: President, Walden UniversityCIK: 0001928817
Associated companies
Transaction History
| CVSA | ▼ Sell | Tax Withholding | 945 | $125K | 8/23/2026 | View on chart |
| CVSA | ▲ Buy | Grant | 7,320 | $969K | 8/23/2026 | View on chart |
| CVSA | ▼ Sell | Tax Withholding | 3,302 | $437K | 8/23/2026 | View on chart |
| CVSA | ▲ Buy | Grant | 5,124 | $678K | 8/23/2026 | View on chart |
| CVSA | ▼ Sell | Tax Withholding | 2,311 | $306K | 8/23/2026 | View on chart |
| CVSA | ▼ Sell | Tax Withholding | 441 | $42K | 11/13/2025 | View on chart |
| CVSA | ▲ Buy | Grant | 5,575 | $540K | 11/12/2025 | View on chart |
| CVSA | ▼ Sell | Tax Withholding | 4,673 | $630K | 8/24/2025 | View on chart |
| CVSA | ▼ Sell | Tax Withholding | 770 | $104K | 8/24/2025 | View on chart |
| CVSA | ▲ Buy | Grant | 10,840 | $1.5M | 8/24/2025 | View on chart |
| CVSA | ▼ Sell | Tax Withholding | 5,113 | $690K | 8/23/2025 | View on chart |
| CVSA | ▲ Buy | Grant | 11,890 | $1.6M | 8/23/2025 | View on chart |
| CVSA | ▼ Sell | Tax Withholding | 903 | $122K | 8/23/2025 | View on chart |
| CVSA | ▼ Sell | Open Market | 3,500 | $380K | 2/6/2025 | View on chart |
| CVSA | ▲ Buy | Grant | 3,070 | $276K | 11/13/2024 | View on chart |
| CVSA | ▼ Sell | Tax Withholding | 779 | $59K | 8/24/2024 | View on chart |
| CVSA | ▼ Sell | Tax Withholding | 884 | $67K | 8/23/2024 | View on chart |
| CVSA | ▼ Sell | Tax Withholding | 1,635 | $107K | 5/18/2024 | View on chart |
| CVSA | ▼ Sell | Tax Withholding | 530 | $23K | 8/24/2023 | View on chart |
| CVSA | ▲ Buy | Grant | 6,280 | $269K | 8/23/2023 | View on chart |
| CVSA | ▼ Sell | Tax Withholding | 1,621 | $70K | 5/18/2023 | View on chart |
| CVSA | ▲ Buy | Grant | 5,440 | $216K | 8/24/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
Covista receives mixed analyst coverage and rating update
Recent commentary on Covista is mixed. ChartMill describes the stock as a GARP case with reasonable growth and valuation. Yahoo published both a target‑focused piece and a separate article highlighting reasons to avoid the stock. BMO Capital kept an Outperform rating but lowered its price target to $145.
Covista receives mixed analyst coverage and rating update. Recent commentary on Covista is mixed. ChartMill describes the stock as a GARP case with reasonable growth and valuation. Yahoo published both a target‑focused piece and a separate article highlighting reasons to avoid the stock. BMO Capital kept an Outperform rating but lowered its price target to $145.